RE: AACR - Poster 22/6/2020 - SRA73724 Jun 2020 15:01
YES BASS, thanks for the link what a good review and write up
Professor Udai Banerji, Deputy Director of the Drug Development Unit at the ICR and The Royal Marsden, said:
“These studies have shown the potential of SRA737 as a possible future treatment for a range of cancer types, with some encouraging results in combination with low-dose chemotherapy in anogenital cancers.
“It’s a pleasure to see a drug discovered here at the ICR and progressed through development with our partners show potential as a future treatment. Hopefully, further trials will firmly establish the effectiveness of the drug and provide a new option for patients for whom new options are urgently needed.
“Now that the dose and schedules of administration have been established in cancer patients, it will be possible to explore further combinations of SRA737 with other drugs across different cancers where very interesting preclinical data has been seen.’’
An innovative, highly targeted treatment
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:
“At the ICR, we believe that the future of cancer treatment is precision medicines, increasingly used as part of drug combinations, that exploit genetic weaknesses within cancer to overcome or delay drug resistance.
“The Chk1 inhibitor SRA737, which was discovered at the ICR with our partners Cancer Research UK and Sareum and is now being taken forward by Sierra Oncology, is an excellent example of such an innovative, highly targeted treatment.
AND THEN SIERRA SHELVE IT AFTER ALL THAT and start FING ABOUT WHY???????